Skip to main content
SpringerLink
Log in

Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Pasireotide (Signifor®) long-acting release (LAR) is a next-generation somatostatin receptor ligand (SRL) approved for treatment of patients with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. Pasireotide LAR has been shown to be more effective than other SRLs in providing biochemical control in patients with acromegaly. However, hyperglycemia-related adverse events were more frequent in patients treated with pasireotide LAR than in those treated with other SRLs. Given the effectiveness of pasireotide LAR, it is important to understand whether these hyperglycemia-related events are manageable and, if so, the appropriate steps to take to manage them. In patients treated with pasireotide LAR, levels of fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) increased in the first 1–3 months and stabilized for as long as 26 months thereafter. In phase III trials of patients with acromegaly, only 3.4–3.8 % discontinued pasireotide LAR because of hyperglycemia-related adverse events. In cases in which pasireotide LAR was discontinued, FPG and HbA1c levels returned to baseline. Frequent monitoring of glucose levels is recommended, especially immediately after initiating and discontinuing pasireotide LAR. The treatment strategies suggested herein are made on the basis of available clinical data from healthy volunteers and post hoc analyses of phase III trials. Data from several clinical trials indicate a predictable and possibly reversible hyperglycemic effect that is manageable with proactive monitoring and available antidiabetic medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

(Adapted with permission from [36]

Fig. 2

(Adapted with permission from [39]

Fig. 3

(Adapted with permission from [34]

Fig. 4

Similar content being viewed by others

References

  1. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am. 2008;37(1):101–22, viii.

  2. Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:540398.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95.

    Article  CAS  PubMed  Google Scholar 

  4. Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–8.

    Article  CAS  PubMed  Google Scholar 

  5. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract. 2011;17(suppl 4):1–44.

    Article  PubMed  Google Scholar 

  6. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51.

    Article  CAS  PubMed  Google Scholar 

  7. Signifor LAR [package insert]. East Hanover: Novartis Pharmaceuticals Corporation; 2014.

  8. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84.

    Article  CAS  PubMed  Google Scholar 

  10. Signifor LAR [summary of product characteristics]. Basel: Novartis Pharma AG; 2014.

  11. Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17(2):180–6.

    Article  CAS  PubMed  Google Scholar 

  12. Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, et al. Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34–41.

    Article  CAS  PubMed  Google Scholar 

  13. Golkowski F, Krzentowska-Korek A, Baldys-Waligorska A, Hubalewska-Dydejczyk A. Goiter, cardiovascular and metabolic disorders in patients with acromegaly. Endocr Regul. 2011;45(4):191–7.

    Article  CAS  PubMed  Google Scholar 

  14. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab. 2004;89(2):658–61.

    Article  CAS  PubMed  Google Scholar 

  15. Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014;17(1):81–9.

    Article  CAS  PubMed  Google Scholar 

  16. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol. 2000;52(5):549–55.

    Article  CAS  Google Scholar 

  17. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–77.

    Article  PubMed  Google Scholar 

  18. Moller N, Jorgensen JO, Alberti KG, Flyvbjerg A, Schmitz O. Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man. J Clin Endocrinol Metab. 1990;70(4):1179–86.

    Article  CAS  PubMed  Google Scholar 

  19. Chen Y, Sun D, Krishnamurthy VM, Rabkin R. Endotoxin attenuates growth hormone-induced hepatic insulin-like growth factor I expression by inhibiting JAK2/STAT5 signal transduction and STAT5b DNA binding. Am J Physiol Endocrinol Metab. 2007;292(6):E1856–62.

    Article  CAS  PubMed  Google Scholar 

  20. Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest. 2004;113(1):25–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41(2):425–43, vii-viii.

  22. Burks DJ, White MF. IRS proteins and beta-cell function. Diabetes. 2001;50(Suppl 1):S140–5.

    Article  CAS  PubMed  Google Scholar 

  23. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose–response relationships in healthy young and middle-aged adults. J Clin Invest. 1994;93(3):1131–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. O’Connell T, Clemmons DR. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab. 2002;87(9):4356–60.

    Article  PubMed  Google Scholar 

  25. Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK, et al. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest. 2009;32(11):924–33.

    Article  CAS  PubMed  Google Scholar 

  26. Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, et al. Lanreotide Autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer. 2006;107(10):2474–81.

    Article  CAS  PubMed  Google Scholar 

  27. Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metabol. 2007;92(2):673–80.

    Article  CAS  Google Scholar 

  28. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–16.

    Article  CAS  PubMed  Google Scholar 

  29. Atiya AW, Moldovan S, Adrian TE, Coy D, Walsh J, Brunicardi FC. Intraislet somatostatin inhibits insulin (via a subtype-2 somatostatin receptor) but not islet amyloid polypeptide secretion in the isolated perfused human pancreas. J Gastrointest Surg. 1997;1(3):251–6 (discussion 6).

    Article  CAS  PubMed  Google Scholar 

  30. Tzanela M, Vassiliadi DA, Gavalas N, Szabo A, Margelou E, Valatsou A, et al. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol. 2011;75(1):96–102.

    Article  CAS  Google Scholar 

  31. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500–8.

    Article  CAS  PubMed  Google Scholar 

  32. Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol. 2012;212(1):49–60.

    Article  CAS  PubMed  Google Scholar 

  33. Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET, et al. Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues. Regul Pept. 2007;138(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  34. Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary. 2015;18(3):385–94.

    Article  CAS  PubMed  Google Scholar 

  35. Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine. 2016;53(1):210–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–53.

    Article  CAS  PubMed  Google Scholar 

  37. Plockinger U, Holst JJ, Messerschmidt D, Hopfenmuller W, Quabbe HJ. Octreotide suppresses the incretin glucagon-like peptide (7–36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects. Eur J Endocrinol. 1999;140(6):538–44.

    Article  CAS  PubMed  Google Scholar 

  38. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab. 2000;278(6):E1010–8.

    CAS  PubMed  Google Scholar 

  39. Breitschaft A, Hu K, Hermosillo Resendiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014;103(3):458–65.

    Article  CAS  PubMed  Google Scholar 

  40. Colao A, Gu F, Gadelha MR, van der Lely AJ, Fleseriu M, Passos VQ, et al. Metformin-based oral antidiabetic therapy is effective at controlling hyperglycemia associated with pasireotide in patients with acromegaly. Poster presented at: 97th Endocrine Society Annual Meeting and Expo; March 5–8, 2015; San Diego, CA.

  41. Wildemberg LE, Gadelha MR. Pasireotide for the treatment of acromegaly. Expert Opin Pharmacother. 2016;17(4):579–88.

    Article  CAS  PubMed  Google Scholar 

  42. Fleseriu, M, Rusch E, Warsi G, Geer EB, on behalf of the ACCESS study investigators. Safety and tolerability of pasireotide long-acting release in acromegaly–results from the acromegaly, open-label, multi-center, safety monitoring program for treating patients who have need to receive medical therapy (ACCESS) study. Poster presented at: 97th Endocrine Society Annual Meeting and Expo; April 1–4, 2016; Boston, MA.

  43. Lu L, Duan L, Jin Z, Lu Z, Gu F. Effective long-term treatment of Cushing’s disease with pasireotide: a case report. Endocr Prac. 2013;19(4):e92–6.

    Article  Google Scholar 

  44. MacKenzie Feder J, Bourdeau I, Vallette S, Beauregard H, Ste-Marie LG, Lacroix A. Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III trial. Pituitary. 2014;17(6):519–29.

    Article  CAS  PubMed  Google Scholar 

  45. Freda P, Fleseriu M, van der Lely AJ, Colao A, Sheppard A, Gu F et al. Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, phase III study. Poster presented at: 15th European Congress of Endocrinology; April 27–May 1, 2013; Copenhagen, Denmark.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, The Pituitary Center, Baylor St. Luke’s Medical Center, Baylor College of Medicine, One Baylor Plaza, ABBR R615, Houston, Texas, 77030, USA

    Susan L. Samson

Authors
  1. Susan L. Samson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan L. Samson.

Ethics declarations

Funding

Editorial assistance under the author’s direction was provided by MedThink SciCom and was supported by Novartis Pharmaceuticals Corporation.

Conflict of interest

Susan L. Samson is a member of the pasireotide study group and has been a site principal investigator for SOM230 clinical trials involving acromegaly and Cushing’s disease. She is the recipient of an investigator-initiated grant on pasireotide effects on β-cell function and replication. She also is a steering committee member for the ongoing SOM230B2219 trial.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samson, S.L. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. Drugs 76, 1235–1243 (2016). https://doi.org/10.1007/s40265-016-0615-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0615-y

Keywords

Search

Navigation